PE Tech Report


Like this article?

Sign up to our free newsletter

Avoro Ventures adds Partner

Avoro Ventures, a global venture capital firm focused on investments in companies operating in the life sciences and biotechnology sectors, has added to its team with the appointment of Mark Chin as a Partner.

Chin, who has 15 years of healthcare experience across venture capital, will be joining Uya Chuluunbaatar, PhD, as an Investment Partner working with Behzad Aghazadeh, PhD, Managing Partner of Avoro Ventures, and Garheng Kong, MD/PhD, Avoro Ventures Advisory Partner.

Prior to joining Avoro Ventures, Chin was a Managing Director at Arix Bioscience focused on private and public biotech investments. During his time at Arix, he sourced and led 10 private biotech investments resulting in 4 IPOs, 2 reverse mergers, and 2 acquisitions. Prior to Arix, Chin was a Principal at Longitude Capital, where he focused on investments in biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group and worked in corporate development at Gilead Sciences and market planning at Genentech.

Like this article? Sign up to our free newsletter